PUBLISHER: The Business Research Company | PRODUCT CODE: 1760525
PUBLISHER: The Business Research Company | PRODUCT CODE: 1760525
Divalproex sodium is a prescribed drug used to treat various neurological and psychiatric conditions. It is a combination of sodium valproate and valproic acid, which function by boosting the levels of gamma-aminobutyric acid (GABA) in the brain. GABA is a chemical that helps decrease excessive nerve activity. By stabilizing the brain's electrical signals, this medication promotes mental and neurological equilibrium.
Divalproex sodium is available in several forms, including tablets, capsules, extended-release tablets, and more. Tablets are solid oral dosage forms that contain the active ingredients, pressed into a specific shape for easy administration. It can be taken orally or intravenously and is used to treat conditions including epilepsy, bipolar disorder, migraine prevention, and neuropsychiatric disorders. The drug is available through hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels.
The divalproex sodium market research report is one of a series of new reports from The Business Research Company that provides divalproex sodium market statistics, including divalproex sodium industry global market size, regional shares, competitors with a divalproex sodium market share, divalproex sodium market segments, market trends and opportunities, and any further data you may need to thrive in the divalproex sodium. This divalproex sodium market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The divalproex sodium market size has grown strongly in recent years. It will grow from $1.83 billion in 2024 to $1.97 billion in 2025 at a compound annual growth rate (CAGR) of 7.4%. The growth observed during the historical period can be credited to several factors, including increased healthcare spending, the expansion of pharmaceutical distribution networks, a rising demand for outpatient and home-based treatments, government reimbursement and insurance assistance, and a growing need for chronic disease management.
The divalproex sodium market size is expected to see strong growth in the next few years. It will grow to $2.60 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth anticipated during the forecast period can be attributed to the rising prevalence of epilepsy, the increasing incidence of bipolar disorder, higher diagnosis rates of migraine disorders, a growing elderly population susceptible to neurological conditions, and expanded access to healthcare. Key trends in this period include advancements in drug formulation methods, increased research on central nervous system (CNS) disorders, innovations in drug delivery systems, enhanced diagnostic tools for epilepsy and bipolar disorders, and the development of biomarkers for targeted treatments.
The increasing prevalence of neurological disorders is expected to drive the growth of the divalproex sodium market in the future. Neurological disorders are conditions that affect the brain, spinal cord, or nerves, leading to impairments in function and symptoms such as muscle weakness, seizures, or cognitive difficulties. As life expectancy rises, the aging population becomes more susceptible to conditions including Alzheimer's and Parkinson's, which tend to develop later in life. Divalproex sodium plays a crucial role in managing neurological disorders by stabilizing electrical activity in the brain, preventing seizures, and controlling mood swings, which are common in conditions including epilepsy and bipolar disorder. For example, data from the Centers for Disease Control and Prevention (CDC) in May 2024 revealed that approximately 2.9 million U.S. adults aged 18 and older had active epilepsy in 2021 and 2022, accounting for about 1% of the adult population in the U.S. As the prevalence of neurological disorders rises, the demand for divalproex sodium is expected to grow.
Key players in the divalproex sodium market are concentrating on developing innovative solutions, such as extended-release tablets, to improve patient compliance. These tablets are designed to release their active ingredient gradually over time, enabling less frequent dosing and providing more consistent therapeutic effects. For example, in March 2022, Unichem Laboratories, a pharmaceutical company based in India, received approval from the U.S. Food and Drug Administration (FDA) for its generic version of Divalproex Sodium extended-release tablets in 250 mg and 500 mg dosages. These tablets are used to treat acute manic or mixed episodes associated with bipolar disorder, both as a standalone treatment and in combination with other therapies, as well as for preventing migraine headaches.
In June 2024, Lotus Pharmaceuticals, a pharmaceutical company based in Taiwan, acquired the Thailand business and commercial operations of Teva Pharmaceuticals for an undisclosed amount. Following the acquisition, Lotus will assume responsibility for marketing and selling Teva Pharma Thailand's current product portfolio, which will become a wholly owned subsidiary of Teva. This acquisition will allow Lotus to expand its presence in Thailand by adding respiratory and ophthalmic products to its offerings and growing its local workforce to approximately 100 employees. The move will enhance Lotus's ability to reach more hospitals and pharmacies in the region. Teva Pharmaceuticals is an Israel-based manufacturer of divalproex sodium.
Major players in the divalproex sodium market are AbbVie Inc., Sanofi S.A., Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies Inc., Aurobindo Pharma Limited, Hikma Pharmaceuticals Public Limited Company, Amneal Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Alkem Laboratories Limited, Alembic Pharmaceuticals Limited, Supernus Pharmaceuticals Inc., Strides Pharma Science Limited, Upsher-Smith Laboratories LLC, Ajanta Pharma Limited, Ishita Active Pharmaceutical Ingredients, Varahi International, Roaq Chemicals Private Limited, and MSN Laboratories Private Limited.
North America was the largest region in the divalproex sodium market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in divalproex sodium report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the divalproex sodium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The divalproex sodium market consists of sales of valproic acid oral solution, carbamazepine tablets, and lamotrigine tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Divalproex Sodium Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on divalproex sodium market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for divalproex sodium ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The divalproex sodium market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.